Skip to main content

Subuxone Manufacturer To Pay $102.5M Over Antitrust Claims

Subuxone Manufacturer To Pay $102.5M Over Antitrust Claims

Subuxone Manufacturer To Pay $102.5M Over Antitrust Claims

Introduction

Opioid addiction treatment drug Suboxone's manufacturer has agreed to pay $102.5 million to the District of Columbia, 41 states, and other jurisdictions in order to resolve allegations that it used unfair business practices.

The settlement with North Chesterfield, Virginia-based Indivior prevents a trial that was set to begin later this year. States, led by Wisconsin, said that the business, which was formerly a division of Reckitt Benckiser Pharmaceuticals, modified Suboxone just slightly so order to prolong its patent protection and prevent the release of generic copies of the medication.

A marketed version of buprenorphine with naloxone is called Suboxone. The lawsuit is separate from accusations made by governments against other opioid manufacturers that they contributed to or exacerbated a national overdose problem. Settlements resulting from those have so far cost more than $50 billion.

Indivior is required under the agreement to inform the states of any changes to its products or corporate control. In a statement, the business said that by resolving the litigation, it will be able to concentrate on its goals.

2019 saw Reckitt Benckiser reach an agreement to pay the federal government $1.4 billion in order to settle any possible legal issues relating to its Suboxone business.

Attorneys general from the following states, in addition to Wisconsin, are represented in the settlement: Alabama, Alaska, Arkansas, California, Colorado, District of Columbia, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Hampshire, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Virginia, Washington and West Virginia.

In 2016, the producers of Suboxone were accused of unlawful trade restriction and conspiracy to monopolize by the former attorney general of Maryland and 35 other attorneys general.

Suboxone prevents withdrawal symptoms and lowers cravings by binding to opioid receptors in the brain.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Tepezza Hearing Loss MDL: Bellwether Trials Set for 2026

Categories: Tepezza

A U.S. District Judge overseeing Tepezza hearing damage lawsuits nationwide has scheduled four bellwether trials for 2026. These trials are intended to help both parties assess how juries may respond to the evidence and testimonies that could be…

3M Moves to Dismiss 100+ Bair Hugger Infection Lawsuits

Categories: Bair Hugger System

Nearly a decade after litigation first began, 3M Company continues to face thousands of lawsuits over its Bair Hugger warming blankets, which have been linked to…

Bayer May Issue New Stock to Fund Roundup Settlements

Categories: Roundup

Bayer has announced plans to issue new shares to finance legal settlements and ongoing litigation costs related to Roundup.
The company is also contemplating withdrawing its…

🎁 March VIP Medical Record Review Offer – Get 300 Pages Free!          
Includes a Free Life Care Plan Report + 10% Off Future Reviews!

Only 7 spots left out of 15—first come, first served!